Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.48 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908298 | 0.90 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAHTTPOLB | |
| SCHEMBL2902827 | 0.85 | FAAH (0.51) | KMT2AMEN1ATMGPR183SIGMAR1 | |
| SCHEMBL2908745 | 0.84 | DRD4 (0.49) | ALDH1A1KDM4EHTTKMT2AMEN1 | |
| SCHEMBL2906184 | 0.83 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAHTTPOLB | |
| SCHEMBL2905864 | 0.83 | KDM4E (0.58) | ALDH1A1KDM4ELMNAHTTPOLB | |
| SCHEMBL2906206 | 0.83 | ALDH1A1 (0.48) | ALDH1A1KDM4ELMNAHTTPOLB | |
| SCHEMBL2909991 | 0.81 | KDM4E (0.57) | ALDH1A1KDM4ELMNAHTTKMT2A | |
| SCHEMBL2903733 | 0.81 | ALDH1A1 (0.60) | ALDH1A1KDM4ELMNAHTTKMT2A | |
| SCHEMBL2903324 | 0.80 | FAAH (0.52) | ALDH1A1KDM4ELMNAHTTPOLB | |
| SCHEMBL2905333 | 0.80 | OPRM1 (0.52) | KMT2AMEN1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PEREZ MICHEL (FR) | 2012-09-13 | — | — | US | claimed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | claimed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | claimed |
| EP-2041104-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | Pierre Fabre Medicament (FR) | 2009-04-01 | — | — | EP | claimed |
| WO-2007147824-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | claimed |
| US-8513258-B2 | Cinnamoyl-piperazine derivatives and their use as par-1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2013-08-20 | — | — | US | disclosed |
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PEREZ MICHEL (FR) | 2012-09-13 | — | — | US | disclosed |
| US-8217046-B2 | Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2012-07-10 | — | — | US | disclosed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2041104-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | Pierre Fabre Medicament (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007147824-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | ALDH1A1 1137/4885KDM4E 3494/4885LMNA 1615/4885 |
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | ALDH1A1 1137/4885KDM4E 3494/4885LMNA 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.